Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health [0.03%]
法国国家卫生管理局的制造商关于健康技术评估的健康状态功效估计综述
Françoise F Hamers,Salah Ghabri,Catherine Le Gales
Françoise F Hamers
Background: Our aim was to review the selection and methods used for deriving health state utility (HSU) estimates included in the cost-utility analyses (CUA) submitted by manufacturers to the National Authority for Healt...
The insights of health and welfare professionals on hurdles that impede economic evaluations of welfare interventions [0.03%]
卫生与福利专业人士关于阻碍福利干预经济效益评估的难题的见解
J Schepers,J Plaete,I De Bourdeaudhuij et al.
J Schepers et al.
Background: Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-s...
Usha Sambamoorthi,Drishti Shah,Xiaohui Zhao
Usha Sambamoorthi
Arthritis and depression are two of the top disabling conditions. When arthritis and depression exist in the same individual, they can interact with each other negatively and pose a significant healthcare burden on the patients, their famil...
Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models [0.03%]
粒细胞集落刺激因子在预防发热性中性粒细胞减少症中的作用：成本效益模型回顾
Kelly Fust,Anju Parthan,Michael Maschio et al.
Kelly Fust et al.
We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention of febrile neutropenia (FN) in patients receiving myelosuppressive cance...
Validation and calibration of structural models that combine information from multiple sources [0.03%]
综合利用多种信息源的结构模型的验证和校准
Issa J Dahabreh,John B Wong,Thomas A Trikalinos
Issa J Dahabreh
Mathematical models that attempt to capture structural relationships between their components and combine information from multiple sources are increasingly used in medicine. Areas covered: We provide an overview of methods for model valida...
Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea [0.03%]
韩国抗癌药物报销决策标准的社会偏好调研
Sun-Hong Kwon,Sun-Kyeong Park,Ji-Hye Byun et al.
Sun-Hong Kwon et al.
Introduction: In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to e...
National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea [0.03%]
韩国2007至2016年58种抗癌药物全国统一报销评审因素的回顾性分析
Eun-Sook Kim,Jung-Ae Kim,Eui-Kyung Lee
Eun-Sook Kim
Background: Since the positive-list system was introduced, concerns have been raised over restricting access to new cancer drugs in Korea. Policy changes in the decision-making process, such as risk-sharing agreement and ...
A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models [0.03%]
个性化医学卫生经济学面临的挑战及患者层面经济模型的实施展望系统综述与清单
Koen Degeling,Hendrik Koffijberg,Maarten J IJzerman
Koen Degeling
The ongoing development of genomic medicine and the use of molecular and imaging markers in personalized medicine (PM) has arguably challenged the field of health economic modeling (HEM). This study aims to provide detailed insights into th...
A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder [0.03%]
注意缺陷多动障碍治疗的长期经济模型的概念框架
Balázs Nagy,Juliana Setyawan,David Coghill et al.
Balázs Nagy et al.
Background: Models incorporating long-term outcomes (LTOs) are not available to assess the health economic impact of attention-deficit/hyperactivity disorder (ADHD). ...
The impact of price-cap regulations on market entry by generic pharmaceutical firms [0.03%]
价格调控对仿制制药企业进入市场的影响分析
Wei Zhang,Huiying Sun,Daphne Guh et al.
Wei Zhang et al.
Background: In 1998, the province of Ontario, Canada implemented price-cap '70/90' regulations: the first generic must be priced at ≤70% of the associated brand-name price and subsequent generics must be priced at ≤90% ...